Stockopedia | Share Prices, Share News and Company Research

MOMENTUM
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d vs 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
GROWTH & VALUE

IMPLIED MARGIN OF SAFETY (beta)
SCREENS PASSED 1
Balance Sheet · Income Statement · Cashflow FINANCIAL SUMMARY
Year End 31st Mar 2007 2008 2009 2010 2011 2012 TTM 2013E 2014E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -25.9%

FINANCIAL BRIEF: For the six months ended 30 September 2012, Byotrol Plc revenues increased 11% to L1M. Net loss decreased 51% to L677K. Revenues reflect UK segment increase of 42% to L798K. Lower net loss reflects Depreciation decrease of 1% to L25K (expense), Finance Income increase from L0K to L1K (income). more »

HEALTH TREND

BANKRUPTCY RISK

  EARNINGS MANIPULATION RISK

MAGIC FORMULA SCORE  
E+
E+

OTHER RATIOS
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
RECENT HISTORY
Latest interim period (ended 30th Sep '12) vs. prior year
Sales Growth %
EPS Growth %
3yr Average Annualised
Sales Growth %
EPS Growth %
DPS Growth %

BROKER FORECASTS
31st Mar 2013
31st Mar 2014

Price Target: 15.0p (+94.81% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
BROKER CONSENSUS & FORECAST TREND
Broker Recommendations for Byotrol
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Arbuthnot Securities (Hist) , Edison Investment Research Nigel Harrison , FinnCap Keith Redpath ,

Byotrol plc is a United Kingdom-based company. The Company is engaged in the development, patenting and sale of products based on microbial technology. The Company operates in three segments: being product sales, licence fees and royalties. The Company manufactures products based on microbial technology in the United Kingdom and also generates revenues from licensing agreements. Its customers are based in the United Kingdom, North America and Worldwide. The Company's operations are located in the United Kingdom and the United States of America. Its principal activity is to market and sell consumer products. The Company's wholly owned subsidiaries include Byotrol Technology Limited and Byotrol Inc, both are engaged in antimicrobial products business.

Directors: Gary Millar (CEO) 51, Duncan Grosvenor (Fin. Dir.) 34, Richard Bell (Secy.) 61,

No. of Employees: 30 No. of Shareholders: n/a


Last Annual March 31st, 2012
Last Interim September 30th, 2012
Shares in Issue 143,579,676
Free Float 124.1m (86.4%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

BYOT SHARE PRICE PERFORMANCE BYOT QUOTE
BYOT Share Price GBp
8p
Day's Change
0.1  1.6%
Traded 11:08am · Minimum 15 min delayed

LATEST BYOT NEWS ANNOUNCEMENTS (delayed)

UPCOMING BYOT EVENTS
No upcoming events.
Recent ↓
Tuesday 20th November, 2012
Interim 2012 Byotrol Plc Earnings Release
Thursday 19th July, 2012
Byotrol Plc Annual Shareholder Meeting
Tuesday 19th June, 2012
Preliminary 2011 Byotrol Plc Earnings Release
Thursday 12th April, 2012
2011/2012 Byotrol Plc Trading Update for the year to 31 March 2012
Thursday 21st July, 2011
Byotrol Plc Shareholders Meeting
Tuesday 21st June, 2011
Preliminary 2011 Byotrol Plc Earnings Release
Wednesday 11th August, 2010
Byotrol PLC Secondary Public Offering Pricing


Should you buy BYOT

Access BYOT Analytics Now!

FREE TRIAL or TAKE THE TOUR